Fact CheckerSign in

NCT07700212Not yet recruitingPhase 1

A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma

Source: ClinicalTrials.gov · Last updated 14 Aug 2026

Brief summary (registry, in English)

The goal of this clinical research study is to learn about the safety and tolerability of the OnVagus device when used by patients who have metastatic pancreatic cancer and are receiving chemotherapy.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
10 (estimated)
First submitted
8 Jul 2026
Start date
Sept 2026
Primary completion date
Dec 2026
Lead sponsor
M.D. Anderson Cancer Center
NCT number
NCT07700212

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 10
  • From Sept 2026 to the primary completion date, Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Implanted electrical device that passes through the neck (e.g.: cranial implant with battery pack in chest, and wires running through the neck).
  • Metal implants in the neck, including the cervical spine.
  • Prior severe cerebrovascular disease (e.g., intracranial aneurysm, intracranial hemorrhage, stroke).
  • Prior severe cardiac disease, including but not limited to coronary artery disease (CAD), prior myocardial infarction (MI), uncontrolled congestive heart failure (CHF).

Other illness

  • History of cervical vagotomy on the right side of neck.

Other

  • Known structural abnormalities on the right side of neck, including but not limited to situs inversus, bulky R-neck lymphadenopathy, etc., that in the investigators' opinion would lead to inability to correctly place the device onto the vagus nerve.
  • Recent (6 months or less) nerve block or botox injections to the head or neck.
  • Pain specifically localized to the treatment area, the right side of the neck.

Who the study is looking for

  • Patients with metastatic pancreatic cancer.
  • Must have adenocarcinoma component (presence of combined histology is acceptable, as long as adenocarcinoma is present).
  • Weight loss from baseline of at least 5% (Baseline weight can be anytime from diagnosis onward).
  • Must have a tissue-based confirmation of diagnosis available. Tissue does not need to be a metastasis; primary tumor or prior surgery are acceptable sources.
  • Must have had progression of disease after one prior line of therapy in the metastatic setting.
  • Must be receiving or plan to receive another line of therapy in the metastatic setting. o If therapy is being administered outside MD Anderson, the patient is still eligible for this trial. o Enrollment onto a therapeutic clinical trial as this second line therapy is not explicitly excluded.
  • Must have triple ECG results available. Patients will be ineligible if they present: o Second- or third-degree block.
    • Prolonged QT wave.
    • Atrial fibrillation or flutter.
    • Uncontrolled ventricular fibrillation or flutter.
    • Premature ventricular contractions (PVC).

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
UT MD Anderson
Coordinator of this site? Confirm its status
HoustonUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.